Monoclonal antibodies that block IL-6 signaling, such as anti-IL-6 R agents (e.g., tocilizumab), have already demonstrated efficacy in systemic inflammatory disorders, including rheumatoid arthritis and juvenile idiopathic arthritis. The gene discussed is IL6; the disease is rheumatoid arthritis.